High Frequencies and co-existing of myositis-specific autoantibodies in patients with idiopathic inflammatory myopathies overlapped to rheumatoid arthritis

Nakajima, Ayako; Yoshino, Kazuyoshi; Soejima, Makoto; Kawaguchi, Yasushi; Satoh, Takashi; Kuwana, Masataka; Yamanaka, Hisashi

doi:10.1007/s00296-011-1931-x

Cited by 30 publications

(17 citation statements)

References 15 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The coincidence of myopathies and RA has been previously described in case series of patients (7 cases of DM and RA, 16 cases of PM and RA, and 15 cases of unspecified DM or PM associated to RA). However, no uniform criteria or detailed case records can be found regarding these cases and only 8 completely described case reports with clear overlap between RA and DM/PM (Brunasso and Massone, 2011, Martínez—Cordero et al, 2001, Nagashima et al, 2009, Nakajima et al, 2012) can be found in the literature [27–30]. Considering the rarity of the linkage between RA and inflammatory myopathies (DM/PM), most of the cases analyzed in the present study might not represent a sporadic association because of the history of introduction of an anti-TNF- α agent and the improvement after withdrawal of the drug.…”

Section: Discussionmentioning

confidence: 99%

New Onset of Dermatomyositis/Polymyositis during Anti-TNF-αTherapies: A Systematic Literature Review

Brunasso

Aberer

Massone

2014

The Scientific World Journal

View full text Add to dashboard Cite

We performed a systematic search of databases from 1990 to 2013 to identify articles concerning the new onset of dermatomyositis/polymyositis (DM/PM) in patients treated with anti-TNF-α therapy. We retrieved 13 publications describing 20 patients where the new onset of DM/PM after anti-TNF-α therapy was recorded. 17 patients were affected by rheumatoid arthritis (RA), one by Crohn's disease, one by ankylosing spondilytis, and one by seronegative arthritis. In 91% of the cases antinuclear autoantibodies were detected after the introduction of anti-TNF-α therapy. In 6 patients antisynthetase antibodies were detected and other clinical findings as interstitial lung disease (ILD) were recorded. Improvement of DM/PM after anti-TNF suspension (with the concomitant use of other immunosuppressors) was recorded in 94% of cases. The emergence of DM/PM and antisynthetase syndrome seem to be associated with the use of anti-TNF-α agents, especially in patients with chronic inflammatory diseases (mainly RA) with positive autoantibodies before therapy initiation. In particular, physicians should pay attention to patients affected by RA with positive antisynthetase antibodies and/or history of ILD. In those cases, the use of the TNF-α blocking agents may trigger the onset of PM/DM or antisynthetase syndrome or may aggravate/trigger the lung disease.

show abstract

Section: Discussionmentioning

confidence: 99%

New Onset of Dermatomyositis/Polymyositis during Anti-TNF-αTherapies: A Systematic Literature Review

Brunasso

Aberer

Massone

2014

The Scientific World Journal

View full text Add to dashboard Cite

show abstract

“…The MSAs include two classes of cytoplasmic antibodies: those directed against Mi-2 and Mas antigens and others targeting translational proteins such as various tRNA synthetases, the SRP, transcriptional intermediary factor-1 (TIF1;anti-155/140 Ab) and the melanoma differentiation-associated gene-5 (MDA5; anti-CADM140 Ab). 53 While most patients have no detectable MSAs and a rare case may have two detectable MSAs, 54, 55 those that have it carry mostly one MSA type in association with specific HLA haplotypes. 1, 56 …”

Section: Laboratory Studies In Dm Pm and Nmmentioning

confidence: 99%

Idiopathic Inflammatory Myopathies

2014

View full text Add to dashboard Cite

The idiopathic inflammatory myopathies (IIM) consist of rare heterogenous autoimmune disorders that present with marked proximal and symmetric muscle weakness, except for distal and asymmetric weakness in inclusion body myositis (IBM). Besides frequent creatine kinase (CK) elevation, the electromyogram confirms the presence of an irritative myopathy. Extramuscular involvement affects a significant number of cases with interstitial lung disease (ILD), cutaneous in dermatomyositis (DM), systemic or joint manifestations and increased risk of malignancy especially in DM. Myositis specific autoantibodies influence phenotype of the IIM. Jo-1 antibodies are frequently associated with ILD and the newly described HMG-CoA reductase antibodies are characteristic of autoimmune necrotizing myopathy (NM). Muscle pathology ranges from inflammatory exudates of variable distribution, to intact muscle fiber invasion, necrosis, phagocytosis and in the case of IBM rimmed vacuoles and protein deposits. Despite many similarities, the IIM are a quite heterogeneous from the histopathological and pathogenetic standpoints in addition to some clinical and treatment-response difference. The field has witnessed significant advances in our understanding of pathophysiology and treatment of these rare disorders. In this review, we focus on DM, polymyositis (PM) and NM and examine current and promising therapies. The reader interested in more details on IBM is referred to the corresponding chapter in this issue.

show abstract

“…16 Bernstein et al 6 have reported anti-Jo-1 antibodies in the sera of 25% of PM/DM patients, 7.5% of myositis patients without the complication of ILD, 68% of patients with ILD complication, and 3% of patients with ILD in the absence of myositis. In another study, anti-Jo-1 antibodies have also been reported in 15-30% of PM patients and 60-70% of ILD patients.…”

Section: Discussionmentioning

confidence: 99%

The Association of Anti-Aminoacyl-Transfer Ribonucleic Acid Synthetase Antibodies in Patients With Rheumatoid Arthritis and Interstitial Lung Disease

et al. 2018

View full text Add to dashboard Cite

Objectives:This study aims to analyze the distribution and clinicopathological characteristics of anti-aminoacyl-transfer ribonucleic acid (tRNA) synthetase (ARS) antibodies in rheumatoid arthritis patients. Patients and methods:We retrospectively studied the anti-ARS antibody levels in 228 RA patients' (44 males, 184 females; mean age 62.9±14.0 years; range 23 to 88 years) sera from their medical charts. We determined the association with anti-cyclic citrullinated peptide antibody levels, interstitial lung disease (ILD), rheumatoid factor, and methotrexate or biological disease modifying antirheumatic drug treatments. Results: Anti-ARS antibodies were detected in 14 RA patients (6.1%). ILD complications were significantly higher among anti-ARS antibody-positive patients (57.1% vs 22.4%, p<0.05). Levels of anti-threonyl-tRNA-synthetase (anti-PL-7) and anti-alanyl-tRNA-synthetase (anti-PL-12), two anti-ARS antibodies, were higher in RA patients with concurrent ILD (both p<0.05). Myositis and ILD worsening were not observed in three anti-ARS antibodypositive patients despite biological disease modifying antirheumatic drug administration. There was no difference in anti-cyclic citrullinated peptide and rheumatoid factor specificities between patients with or without ARS antibodies. Conclusion: Anti-ARS antibodies were detected in RA patients, with higher prevalence in patients with concurrent ILD. RA patients, specifically those with ILD complications, should be tested for anti-ARS antibodies.

show abstract

High Frequencies and co-existing of myositis-specific autoantibodies in patients with idiopathic inflammatory myopathies overlapped to rheumatoid arthritis

Cited by 30 publications

References 15 publications

New Onset of Dermatomyositis/Polymyositis during Anti-TNF-αTherapies: A Systematic Literature Review

New Onset of Dermatomyositis/Polymyositis during Anti-TNF-αTherapies: A Systematic Literature Review

Idiopathic Inflammatory Myopathies

The Association of Anti-Aminoacyl-Transfer Ribonucleic Acid Synthetase Antibodies in Patients With Rheumatoid Arthritis and Interstitial Lung Disease

Contact Info

Product

Resources

About